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Open Forum Infectious Diseases
MAJOR ARTICLE

Clinical and Genomic Characterization of Recurrent
Enterococcal Bloodstream Infection in Patients With
Acute Leukemia
Julia A. Messina,1 Rohita Sinha,2 Kimberly Starr,3 Mehreen Arshad,4 Barbara D. Alexander,1 Nelson J. Chao,5 and Anthony D. Sung5
1

Division of Infectious Diseases, Department of Medicine, 3Clinical Microbiology Laboratory, Department of Pathology, 4Division of Infectious Diseases, Department of Pediatrics, and 5Division of
Hematologic Malignancies and Cellular Therapies, Department of Medicine, Duke University, Durham, North Carolina; 2Department of Food Science and Technology, University of Nebraska-Lincoln,
Nebraska, Nebraska

Background. Rates and risk factors for recurrent enterococcal bloodstream infection (R-EBSI) and whether the same genetic
lineage causes index EBSI and R-EBSI are unknown in patients with acute leukemia (AL) receiving chemotherapy.
Methods. Ninety-two AL patients with EBSI from 2010 to 2015 were included. Enterococcal bloodstream infection was defined
by 31 positive blood cultures for Enterococcus faecium or Enterococcus faecalis and fever, hypotension, or chills. Clearance was
defined by 31 negative cultures 324 hours after last positive culture and defervescence. Recurrent enterococcal bloodstream infection
was defined by a positive blood culture for Enterococcus 324 hours after clearance. Categorical variables were reported as proportions
and compared by the χ2 test. Continuous variables were summarized by median and interquartile range (IQR) and compared by the
Wilcoxon-Mann-Whitney Test. P values <.05 were considered significant. Whole-genome sequencing was performed on available
paired BSI isolates from 7 patients.
Results. Twenty-four patients (26%) had 31 episodes of R-EBSI. Median time to R-EBSI (IQR) was 26 (13–50) days. Patients
with R-EBSI had significantly longer durations of fever and metronidazole exposure during their index EBSI. Thirty-nine percent
of E. faecium R-EBSI isolates became daptomycin-nonsusceptible Enterococcus (DNSE) following daptomycin therapy for index
EBSI. Whole-genome sequencing analysis confirmed high probability of genetic relatedness of index EBSI and R-EBSI isolates for
4/7 patients.
Conclusions. Recurrent enterococcal bloodstream infection and DNSE are common in patients with AL and tend to occur
within the first 30 days of index EBSI. Duration of fever and metronidazole exposure may be useful in determining risk for R-EBSI.
Whole-genome sequencing analysis demonstrates that the same strain causes both EBSI and R-EBSI in some patients.
Keywords. acute leukemia; daptomycin-nonsusceptible Enterococcus; Enterococcus; recurrent bloodstream infection; whole-genome sequencing.

Enterococcal bloodstream infection (EBSI) occurs commonly
in patients with acute leukemia receiving chemotherapy at rates
of 10.6%–13.9% [1, 2]. However, rates of recurrent enterococcal
BSI (R-EBSI) in this patient population are unknown. In addition, whether the same enterococcal genetic lineage causes the
index EBSI and R-EBSI in this patient population is unknown.
Daptomycin-nonsusceptible Enterococcus faecium (DNSEf)
infection has emerged as a threat to this patient population
with limited antimicrobial treatment options. In a single-center
study of 77 adult patients with acute leukemia and E. faecium
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BSI, 16 (21%) of patients had DNSEf BSI, but rates of DNSEf in
recurrent infection were not reported [3].
Previous studies have identified risk factors for EBSI, mostly
due to E. faecium, such as neutropenia, diarrhea, and antibiotic
administration including vancomycin, metronidazole, and carbapenems [1, 4, 5]. In theory, these risks persist after the index
EBSI as surviving patients will receive more chemotherapy,
leading to more neutropenia and antibiotic exposure.
The primary objective of this study is to identify risk factors for R-EBSI in patients with acute myelogenous leukemia
(AML) or acute lymphoblastic leukemia (ALL). The secondary objective is to determine whether the same enterococcal genetic lineage causes the index EBSI and R-EBSI using
whole-genome sequencing, which offers single-nucleotide
resolution and is less prone to producing false-positive or
false-negative results [6]. We hypothesize that R-EBSI is common in patients with acute leukemia as the risk for reinfection
or relapsed infection persists with immunosuppression from
ongoing chemotherapy, prompting further antimicrobial therapy and gut dysbiosis.
Recurrent Enterococcal Infection • OFID • 1

METHODS
Patient Population

This was a retrospective cohort study of 92 patients receiving
intensive chemotherapy for AML or ALL admitted to Duke
University Medical Center (DUMC) with EBSI from 2010 to
2015. Patients undergoing hematopoietic stem cell transplantation (HSCT) were excluded. Patients were identified as having
a positive blood culture for E. faecium or Enterococcus faecalis
in the DUMC Clinical Microbiology Laboratory (CML) during the study period. This study was approved by the DUMC
Institutional Review Board.
Definitions

Intensive chemotherapy included induction and consolidation
chemotherapy regimens for AML and induction and maintenance therapies for ALL. Bloodstream infection was defined by
US Centers for Disease Control and Prevention (CDC) criteria as mucosal barrier injury laboratory-confirmed BSI (MBILCBI), central line–associated BSI (CLABSI), or unknown [7].
Enterococcal bloodstream infection was defined by 31 positive blood cultures in the DUMC CML for E. faecium or E. faecalis and fever, hypotension, or chills. Bloodstream infection
clearance was defined by 31 negative culture 324 hours after
the last positive culture and defervescence. Fever duration was
defined by the number of consecutive days with a temperature
338°C at the time of EBSI. Recurrent enterococcal BSI was
defined by a positive blood culture for E. faecium or E. faecalis 324 hours after BSI clearance. The definition of R-EBSI was
derived from the definition of recurrent Staphylococcus aureus
BSI [8]. Treatment antibiotics were antibiotics administered
empirically or for treatment of another infection whose start
date was within 1 week before EBSI.
Antimicrobial exposure was defined by receipt of any antimicrobial within 1 week of the index EBSI. These data and
the duration of antimicrobials were obtained through manual
chart review. Appropriate enterococcal therapy was receipt of
an antibiotic with in vitro activity against the EBSI isolate, as
determined by the DUMC CML. Minimum inhibitory concentrations (MIC) were determined by Microscan Gram
Positive Panel Type 29 (Baxter Diagnostics, Inc., MicroScan,
Sacramento, CA). If vancomycin or daptomycin MICs were not
susceptible by the Clinical and Laboratory Standards Institute
guidelines, then MICs were confirmed by Etest (bioMérieux,
Durham, NC).
Enterococcal Bloodstream Isolates

Paired bloodstream isolates available for 7 patients with R-EBSI,
including the index and R-EBSI isolates, were retrieved from
frozen storage from the DUMC CML. Isolates for the remaining
17 patients were either not saved at the time of index or recurrent BSI or could not be found in frozen storage. For patients
who had >1 episode of R-EBSI, only the isolate from the first
episode of R-EBSI was sequenced. Per institutional protocol,
2 • OFID • Messina et al

microbial isolates from patient blood cultures were stored in
glycerol stock at –80°C. Isolates were then plated on trypticase
soy agar plates with 5% sheep blood and incubated for 24 hours
at 37°C with 5% CO2. A lawn of bacterial growth was collected
using a cotton-tipped swab, resuspended into lysogeny broth,
and spun down in a centrifuge to form a cell pellet.
Whole-Genome Sequencing

Genomic DNA for each sample was extracted using the
Agencourt Genfind v2 kit. gDNA was then quantified using
fluorometric quantitation on a Qubit 3.0 fluorometer (Life
Technologies, Carlsbad, CA) using the dsDNA Broad Range
Qubit assay. For each sample, 500 ng of gDNA was then sheared
using a Covaris S220 ultrasonicator to produce approximately
300-bp DNA fragments, following Covaris’ protocol. The
sheared DNA was then used to make DNA-Seq libraries using
the Kapa BioSystem HyperPrep Library Kit (FisherScientific)
following the manufacturer’s protocol. Sheared DNA fragments
were end-repaired, followed by A-tailing. Illumina standard
adapters with unique indexes were ligated, and the library was
then amplified by polymerase chain reaction. Resulting libraries were purified using AmPure beads (Beckman Coulter) and
quantified using fluorometric quantitation on a Qubit 3.0 fluorometer. The fragment size distribution of each library was
checked using an Agilent 2100 Bioanalzyer (Agilent, Santa
Clara, CA). Libraries were pooled into equimolar concentration and loaded on an Illumina MiSeq instrument (24 samples
per lane for a sequencing depth of 50× coverage). Illumina
sequencing was performed using the MiSeq V2 chemistry,
and paired-end reads 150 bp in length were generated. DNA
extraction, library preparation, and sequencing were performed
at the Sequencing and Genomic Technologies Core Facility of
the Duke University Center for Genomic and Computational
Biology.
Statistical and Bioinformatics Analyses

R, version 3.3.2, and R studio, version 1.0.44, were used for
the statistical analysis [9]. Comparisons were made between
characteristics of the index EBSI between patients who did
not have R-EBSI and those who did have R-EBSI. Categorical
variables were reported as proportions and compared by the
χ2 test. Continuous variables were summarized by the median
and interquartile range (IQR) and compared by the WilcoxonMann-Whitney Test. A P value of <.05 was considered statistically significant.
Genomes were assembled using SPAdes Genome Assembler
[10], and gene prediction was performed using Prodigal Gene
Prediction Software [11]. Genome-wide comparison and
identification of shared regions were obtained by aligning
predicted genes of a genome (the smallest genome assembly)
against the rest of the genomes using the BLASTN program
[12]. Subsequently, grammar-based genomic distances between
the shared genomic regions were computed and applied to

generate the phylogenetic tree using the neighbor-joining
method [13, 14]. The phylogenetic tree was annotated using
iTOL, 
version 3 [15]. Pilon was used to determine single
nucleotide 

polymorphisms (SNPs) within the isolates [16].
Whole-genome sequencing data were used to generate the SNP
profiles of the paired BSI samples against the reference genomes
(E. faecium strain ISMMS_VRE_9: NZ_CP018830 and
E. faecalis strain Symbioflor 1: HF558530). Genomes from the
20 randomly selected E. faecium and E. faecalis genomes from
NCBI (Supplementary Table 1) with the highest number of
aligned whole-genome sequencing reads were selected as the
reference genomes for the SNP analysis.
RESULTS

Ninety-two patients receiving intensive chemotherapy for AML
or ALL developed EBSI during the study period. Twenty-four
patients (26%) had 31 episodes of R-EBSI (Table 1). Eighty
patients (87%) had index EBSI due to E. faecium whereas 12
patients (13%) had index BSI due to E. faecalis (Table 2). There
Table 1.

were no significant differences between antibiotic susceptibility
patterns of the index enterococcal BSI isolates between patients
without R-EBSI and patients with R-EBSI.
Among patients with R-EBSI, the median time from index
EBSI to R-EBSI (IQR) was 26 (13–50) days, and E. faecium
was the most common infecting pathogen (23/24; 96%). Four
patients with index EBSI due to E. faecalis during their index
infection had R-EBSI due to E. faecium. Among the patients
with R-EBSI due to E. faecium, 9 (39%) had BSI isolates that converted from daptomycin-susceptible to DNSEf. Three patients
with index EBSI due to vancomycin-resistant E. faecium (VRE)
had R-EBSI due to vancomycin-susceptible E. faecium (paired
isolates were not available in storage for sequencing). Of the 24
patients with R-EBSI, 4 (17%) had >1 episode of R-EBSI. One
patient with 3 episodes of R-EBSI had DNSEf BSI during the
third recurrence following daptomycin therapy for the second
recurrence.
There were no significant differences between time from
leukemia diagnosis to EBSI, history of relapsed or refractory

Baseline Demographics of Index Enterococcal Bloodstream Infection

Characteristic

No Recurrent Enterococcal BSI
(n = 68; 74%)

Recurrent Enterococcal BSI
(n = 24; 26%)

P Value

Female, No. (%)

25 (37)

10 (42)

.48

Age, median (IQR), y

62 (51–70)

61 (46–67)

.58

White

54 (79)

18 (75)

.30

Black

11 (16)

4 (17)

.99

Other

3 (5)

2 (8)

Race, No. (%)

Ethnicity, No. (%)
Hispanic
Non-Hispanic

1 (2)

0

23 (98)

24 (100)

AML

59 (87)

20 (83)

ALL

9 (13)

4 (17)

Underlying disease, No. (%)

9 (38)

.68

Prior hematologic malignancy, No. (%)

16 (24)

Time from leukemia diagnosis to first BSI, median (IQR), d

30 (19–108)

30 (18–164)

.19
.97

52 (77)

18 (75)

.89

7 (10)

2 (8)

First induction chemotherapy regimen
7+3
CALGB
Other

9 (13)

4 (17)

36 (53)

15 (63)

.42

Induction 1

33 (49)

10 (42)

.56

Induction 2

20 (29)

8 (33)

.72

Induction 3

9 (13)

4 (17)

Induction 4

2 (3)

2 (8)

Induction 5

2 (3)

Consolidation, No. (%)

2 (3)

Relapsed/refractory disease at time of BSI
Timing of BSI in relationship to chemotherapy, No. (%)

Prior BSI not due to Enterococcus (since acute leukemia diagnosis), No. (%)

0
0

32 (47)

14 (58)

.34

15 (9–22)

22 (12–32)

.09

8 (5–16)

8 (4–22)

.59

Imipenem/meropenem

19 (14–29)

17 (10–22)

.80

Metronidazole

11 (8–14)

15 (15–17)

.03

Total treatment antibiotic days, median (IQR)
Cefepime
Vancomycin (IV)

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BSI, bloodstream infection; IQR, interquartile range; IV, intravenous.
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Table 2.

Index Enterococcal Bloodstream Infection Characteristics

Characteristic

No Recurrent Enterococcal
BSI (n = 68; 74%)

Recurrent Enterococcal
BSI (n = 24; 26%)

P Value

Length of stay before BSI, median (IQR), d

17 (14–27)

17 (15–29)

Diarrhea at time of BSI, No. (%)

28 (41)

13 (54)

.27

Diarrhea due to Clostridium difficile, No. (%)

14 (21)

4 (17)

.68

Mucositis at time of BSI, No. (%)
Duration of fever with BSI, median (IQR), d

.58

19 (28)

3 (13)

.13

2.5 (1–5)

6 (2–7)

.03

Duration of neutropenia before BSI, median (IQR), d

12 (7–16)

10 (7–19)

.38

Total duration of neutropenia at time of BSI, median
(IQR), d

21 (17–29)

23 (19–76)

.86

3 (1–4)

3 (2–5)

.11

Time to BSI clearance, median (IQR), d
Enterococcus species, No. (%)
E. faecium

61 (90)

19 (79)

E. faecalis

7 (10)

5 (21)

.19

Antibiotic resistance, No. (%)
Ampicillin

54 (79)

16 (67)

.2

Vancomycin

49 (72)

14 (58)

.2

Daptomycin
Polymicrobial BSI, No. (%)

4 (6)
15 (22)

0
4 (17)

.68

Abbreviations: BSI, bloodstream infection; IQR, interquartile range.

leukemia at the time of BSI, or timing of BSI in relationship
to chemotherapy cycle. Patients who developed R-EBSI had a
significantly longer duration of metronidazole exposure at the
time of index EBSI compared with patients without R-EBSI
(15 days; IQR, 15–17 days; vs 11 days; IQR, 8–14 days; P = .03).
Mucosal barrier injury laboratory-confirmed BSI was the most
common source for BSI in both groups based on CDC criteria
with Enterococcus as an intestinal organism and the presence of
neutropenia within 7 days of the positive blood culture in 90 out
of the 92 patients (98%).
Patients who developed R-EBSI had a significantly longer
duration of fever (including time pre- and post-BSI) than
patients who did not have R-EBSI (6 days; IQR, 2–7 days; vs
2.5 days; IQR, 1–5 days; P = .03) (Table 2). There were no significant differences between ampicillin, vancomycin, or daptomycin resistance of the index EBSI isolate or duration of BSI. Two
patients without R-EBSI had secondary sites of enterococcal
infection with their index BSI including meningitis and empyema, whereas no patients with R-EBSI had secondary sites of
infection during their index EBSI.
There were no significant differences between time to appropriate enterococcal therapies and rates of removal of vascular
catheters for the index EBSI (Table 3). Daptomycin was the
most commonly prescribed anti-enterococcal therapy in both
groups (49 patients in both groups). Fifty-three percent of
patients’ therapy was switched, most commonly to linezolid (28
out of 49 patients) at the time of discharge.
Whole-genome sequencing confirmed high probability of
genetic relatedness of index EBSI and R-EBSI isolates in 3 out of 7
patients, inferring that both isolates are from the same enterococcal genetic lineage (Table 4). Of note, patients 1–6 had index and
4 • OFID • Messina et al

R-EBSI due to the same species of Enterococcus whereas patient
7 had an index EBSI due to E. faecalis and R-EBSI due to E. faecium. The paired isolates from patients 1, 3, and 5 were predicted
to have 99.4%, 99.6%, and 99.1% of shared genes with 100% identity, respectively. An analysis of SNPs supported the finding that
patients 1, 3, and 5 have isolates of the same enterococcal genetic
lineage with ≤5 different SNPs, indicating a high degree of genetic
relatedness. Supplementary Data 1 depicts the shared set of genes
between all isolates (the core genomes) that had <95% identity
between the index and R-EBSI isolates. We suspect that these
SNPs caused the identity to drop below the threshold of 95%.
Figure 1 is a phylogenetic tree placing the sequenced isolates
from the 7 patients in this study among the previously characterized E. faecium and E. faecalis isolates. A close phylogenetic
relationship is seen between paired EBSI isolates from patients
1, 3, and 5.

Table 3. Index Enterococcal Bloodstream Infection Outcomes

Characteristic
Vascular catheter removed
for BSI, No. (%)
Time to appropriate antibiotics,
median (IQR), d

No Recurrent
Recurrent
Enterococcal BSI Enterococcal BSI
(n = 68; 74%)
(n = 24; 26%) P Value
34 (50)

11 (46)

2 (1–3)

.73

3 (2–3)

.23

.45

Appropriate enterococcal
antibiotic, No. (%)
Vancomycin

8 (12)

5 (21)

Daptomycin

54 (79)

18 (75)

6 (9)

1 (4)

Other

Abbreviations: BSI, bloodstream infection; IQR, interquartile range.

Table 4.

Patient

Whole-Genome Sequencing of Paired Bloodstream Isolates From 7 Patients

Index BSI
Species

Total Length
of Predicted
Genes,
Shared
Days
Central Line
Megabase
Genes
Recurrent BSI Between Removed for Pairs; Index BSI With >95% Shared Genes With
Species
BSIs
BSI
Isolate
Identity, %
99% Identity, %

Shared
Genes
With 100% Shared SNP Different SNP
Identity, %
Positions
Positions

1

E. faecium E. faecium

8

Yes

2 311 662

99.8

99.8

99.4

5522

5

2

E. faecium E. faecium

25

Yes

2 364 525

92.7

91.0

82.2

2930

51

3

E. faecium E. faecium

15

No

2 311 245

99.8

99.8

99.6

60

1

4

E. faecalis

49

No

2 640 342

85.2

58.7

4

6525

102

E. faecalis

5

E. faecium E. faecium

10

No

2 348 367

99.4

99.4

99.1

76

0

6

E. faecium E. faecium

32

No

2 468 892

85.5

83.4

66.8

3655

29

7

E. faecalis

26

No

2 291 253

0.45

N/A

N/A

E. faecium

0.63

0.60

Abbreviations: BSI, bloodstream infection; SNP, single nucleotide polymorphsim.

DISCUSSION

This is the largest cohort of patients with acute leukemia and
R-EBSI reported to date. R-EBSI is common (26%) in patients
with AML and ALL receiving intensive chemotherapy and
tends to occur within 30 days of the index EBSI. Among the 7
patients for whom paired BSI isolates were available, 43% (3/7)
have index and R-EBSI due the same enterococcal genetic lineage. The use of whole-genome sequencing in the present study
offers greater resolution in comparing strain-relatedness with
traditional techniques such as pulsed-field gel electrophoresis
(PFGE) [6].
Prior studies of R-EBSI have provided conflicting conclusions. In a study of 27 patients with 60 episodes of EBSI over
10 years, 8 patients had infection with isolates from the same
genetic lineage based on multilocus sequence typing. Durations
between BSI episodes ranged from 3 months to 6 years [17]. In
a study of R-EBSI due to VRE BSI, investigators identified 3 out
of 36 patients having R-EBSI due to VRE (8.3%) and analyzed
these isolates for genetic relatedness using PFGE [18].
In a study analyzing 26 R-EBSI isolates from 12 patients using
whole-genome sequencing, investigators found that 10 (71%)
R-EBSI episodes were due to relapsed infection with a different
genetic lineage [19]. Notably, the definition of R-EBSI in this
study only included recurrence ≥30 days after the index BSI.
Based on our findings, we assert that any recurrence, even if
only 1–2 weeks after the index EBSI, is clinically relevant due
to the high risk for DNSEf, potential for subsequent central line
removal, and delays in chemotherapy.
In the present study, traditional clinical factors associated
with risk for recurrent BSI, such as length of hospital stay,
persistent BSI, delay in appropriate antibiotic therapy, failure
to remove the central venous catheter, and secondary sites of
infection, were not associated with R-EBSI. As most of the cases
of EBSI were MBI-LCBI, and DNSEf BSI was more common in
R-EBSI following daptomycin exposure, we suspect that the risk
for R-EBSI is more complicated than what could be explained

by a single clinical risk factor. Theoretically, mucosal barrier
injury from cytotoxic chemotherapy leads to the index EBSI,
which remains a constant risk while patients are still neutropenic. In therapy for acute leukemia, once patients recover their
neutrophil counts, they often go on to receive more chemotherapy, re-introducing the risk for MBI-LCBI. In addition, treatment with daptomycin leads to selective pressure on the gut
microbiota for emergence of DNSEf and potential for recurrent
infection.
Longer fever duration was also a significant risk factor associated with R-EBSI. In a previous study of 909 episodes of febrile
neutropenia and BSI in cancer patients, the investigators found
that patients with complex BSI including a secondary site of
infection such as pneumonia or soft tissue infection had significantly longer durations of fever compared with patients with
simple BSI (and no secondary site of infection) [20]. Patients
with complex BSI were also less likely to achieve a clinical
response to initial antimicrobial therapy.
In the present study, although no patient with R-EBSI had
known secondary sites of infection, fever duration could correlate with a more severe index EBSI with a higher likelihood
of failing initial anti-enterococcal therapy. However, it was
surprising that fever duration was significantly longer among
patients who went on to have R-EBSI, without a significant difference in time to BSI clearance.
Longer metronidazole exposure was also a risk factor for
R-EBSI. A previous study demonstrated that depletion of the
commensal anaerobic gut microbiota in allogeneic HSCT recipients led to reduced gut microbiota diversity and increased risk
of mortality [21]. In another study, investigators found that
metronidazole was a risk factor for reduced microbiota diversity. Metronidazole was also associated with increased risk for
intestinal domination due to Enterococcus, where Enterococcus
accounted for ≥30% of the gut microbiota [22]. In turn, patients
with enterococcal intestinal domination had a 9-fold increased
risk for subsequent VRE BSI.
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Figure 1. Phylogenetic analysis of paired Enterococcus isolates from 7 patients with recurrent enterococcal bloodstream infection in relationship to previously characterized isolates. Patient number 1 represents the enterococcal bloodstream isolate from the index enterococcal bloodstream infection, and patient number 2 represents the
enterococcal bloodstream isolate from the recurrent infection. Paired isolates from each patient are color-coded, with the 2 isolates from the same patient being of the same
color. Reference strain citations are in Supplementary Table 1.

In the present study, R-EBSI due to DNSEf (39%) was notable
and likely due to selective antimicrobial pressure on the gut microbiota from preceding daptomycin therapy. In a study of adult acute
leukemia patients, DiPippo et al. found that receiving daptomycin
for ≥13 days within 90 days of BSI significantly correlated with the
development of DNSEf infection [3]. Based on findings from the
present study, we propose that R-EBSI in addition to prior daptomycin exposure should be taken to account in assessing risk for DNSEf.
Of note, 4 patients in the present study with index DNSEf
BSI did not go on to have R-EBSI. Additionally, none of the
4 patients with DNSEf BSI during their index EBSI had any
known prior daptomycin exposure, which prompts the need
for further investigation into whether the DNSEf isolates were
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hospital-derived isolates that the patients acquired through
environmental contamination or part of the patients’ commensal microbiota at the start of chemotherapy.
Among the 6 patients with available sequencing data and the same
Enterococcus species causing index and R-EBSI, 3 patients had index
and R-EBSI due to the same strain of Enterococcus, and 3 patients had
index and R-EBSI due to different genetic lineages of Enterococcus.
Among the 3 patients with the same infecting genetic lineages, the
duration between the index and R-EBSI ranged from 8–15 days
whereas the duration for the other 3 patients’ index and R-EBSI
ranged from 25 to 49 days. This finding correlates with a previous
study that isolates are more likely to be of the same genetic lineage
when there is a shorter duration between the index and R-EBSI [18].

The present study cannot make conclusions as to whether
central venous catheters should be removed to prevent R-EBSI
due to a limited sample size. However, 2 patients who underwent catheter removal for their index EBSI still had the same
strain of Enterococcus causing R-EBSI, suggesting an alternative source of R-EBSI such as the gastrointestinal tract. In a
prior study of 111 adult patients with enterococcal CLABSI,
the central venous catheter was retained in 29.1% of patients,
and this was not associated with R-EBSI [23]. However, catheter retention was significantly associated with a higher in-hospital mortality rate (37.9% vs 18.3%) following index EBSI.
The authors suggested that the higher in-hospital mortality
rate may have been due to patients being too ill for catheter
removal to be performed safely or having poor vascular access.
Regardless, coupled with our findings, catheter retention may
not lead to R-EBSI, but further investigation is needed into
additional negative outcomes.
Limitations of the present study include the single-center retrospective design and sequencing of paired isolates from only
7 out of 24 patients with R-EBSI. Other centers appear to have
lower rates of EBSI (10.6%–13.9%) in the acute leukemic population compared with DUMC (27%) [24], in addition to possible varying practices with antimicrobial prophylaxis and febrile
neutropenia protocols. Despite E. faecalis accounting for 13%
of the index EBSIs in this study, only 1 patient went on to have
R-EBSI due to E. faecalis, and this limits our ability to generalize
the findings of the clinical and genomic analyses to both E. faecalis and E. faecium infections. For future studies, a larger sample size of patients with R-EBSI will be needed to investigate the
reproducibility of the metronidazole exposure and fever duration as risk factors. Additionally, a larger sample size of paired
bloodstream isolates to investigate the rate of genetic lineage
relatedness will be helpful in determining whether R-EBSI is
due to a re-infection with the same genetic lineage or relapsed
infection with a different genetic lineage.
In conclusion, fever duration may identify patients at risk for
R-EBSI, and reducing metronidazole exposure as an antimicrobial stewardship strategy may prevent R-EBSI. As most patients
with R-EBSI have a gut-derived source of infection, future studies of how gut dysbiosis occurs and how the gut microbiota
repopulates over the course of chemotherapy will be helpful in
determining which patients are at risk for R-EBSI. In addition,
a larger sample size of paired EBSI isolates is needed to draw
conclusions on how frequent R-EBSI episodes are due to the
same genetic lineage as index episodes and whether this finding
is related to central venous catheter retention.
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